Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial
复制标题
DOI：
10.1200/jco.2004.08.119
复制
发表时间：
2004-04-01
影响因子：
45.3
通讯作者：
Rana, J
中科院分区：
文献类型：
--
作者：
Auerbach, M;Ballard, H;Rana, J
重组人促红细胞生成素（rHuEPO）是治疗化疗相关性贫血的标准药物。静脉注射铁剂可改善肾脏疾病贫血患者的血红蛋白（Hb）反应并降低剂量需求，但其效果尚未在癌症患者的随机试验中进行研究。（Hb ≤ 105 g/L，血清铁蛋白≤ 450 pmol/L或：675 pmol/L，转铁蛋白饱和度≤ 19%）每周一次皮下注射rHuEPO 40，000 U：（1）无铁;分别于治疗前和治疗后3个月，观察三组患者的Hb和生活质量（QOL）的变化。结果三组患者的Hb均高于对照组（P
PurposeRecombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients.MethodsThis prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb less than or equal to 105 g/L, serum ferritin less than or equal to 450 pmol/L or : 675 pmol/L with transferrin saturation less than or equal to 19%) receiving subcutaneously rHuEPO 40,000 U once weekly to: (1) no-iron; (2) oral iron 325 mg twice daily; (3) iron dextran repeated 100mg IV bolus; or (4) iron dextran total dose infusion (TDI), Hb and quality of life (QOL) were measured at baseline and throughout.ResultsAll groups showed Hb (P